517 Immunotherapy Applications


Description:
Immunotherapy has emerged as a major breakthrough in modern medicine, offering novel treatment options to otherwise incurable diseases such as metastatic cancer and post-transplant viral infections. This session will focus on engineered protein and cell-based immunotherapy. Topics of interest include but are not limited to antibody therapy, adoptive T-cell therapy, natural killer (NK) cell therapy, and engineered cytokines and other proteins that interface with the immune system.

Sponsor:
Immunotherapy


Chair:
Yvonne Y. Chen
Assistant Professor
University of California, Los Angeles
Chemical and Biomolecular Engineering
420 Westwood Blvd
Los Angeles, CA
90095
Email: yvonne.chen@ucla.edu

Co-Chair:
Wilson Wong
Assistant Professor
Boston University
Biomedical Engineering
Boston, MA
02215
Email: wilwong@bu.edu


Papers:
517a
Fueling Cancer Immunotherapy through Metabolic Reprogramming
Greg Delgoffe, University of Pittsburgh
517b
Macrophage Checkpoint Blockade in a Cell-Based Immunotherapy Can Generate Durable and Safe Cures in a Poorly Immunogenic, Syngeneic Mouse Tumor Model
Lawrence J. Dooling, University of Pennsylvania; Jason C. Andrechak, University of Pennsylvania; Cory Alvey, University of Pennsylvania; Dennis E. Discher, University of Pennsylvania
517c
Development of a Kynureninase Clinical Candidate, a First-in-Class Enzymatic Checkpoint Inhibitor
John Blazeck, University of Texas at Austin; Catrina Somody, UT Austin; Ahlam Qerqez, UT Austin; Kyle Ford, UT Austin; Kendra Garrison, University of Texas at Austin; Christos Karamitros, University of Texas at Austin; Everett Stone, University of Texas at Austin; George Georgiou, The University of Texas at Austin
Break
517d
Immunotherapeutic Targeting of Cancer Cell-Associated Polysialic Acid
Emily C. Cox, Cornell University; Dana N. Thornlow, Cornell University; Michaela A. Jones, Cornell University; Matthew P. DeLisa, Cornell University
517e
Novel Immunomodulatory Peptide Polymers for Vascularized Composite Allograft Rejection Prevention
Xiaofei Wang, University of Missouri; Rui Zhang, University of Missouri; Dylan Weir, University of Missouri; Caitlin Leeper, University of Missouri; Andrew Greenwald, University of Missouri; Bret Ulery, University of Missouri
517f
CO-Delivery of Paclitaxel and Imatinib By PEG Derivatized NLG Carrier As Enhanced Immunochemotherapy
Jieni Xu, University of Pittsburgh
517g
Hybrid Nanoparticle-Based Immunotherapy for Smoking Cessation
Yun Hu, Virginia Tech
Abstract Submissions Closed
See more of this Group/Topical: Topical Conference: Immunotherapy
<< Previous Session | Next Session >>